Mokhtari, S., Asquith, J., Bachmeier, C., Faramand, R., Kim, Y., Peguero, E., . . . Aleksandr, L. (2020). NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY. Neuro Oncol.
शिकागो स्टाइल उद्धरणMokhtari, Sepideh, et al. "NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY." Neuro Oncol 2020.
एमएलए उद्धरणMokhtari, Sepideh, et al. "NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY." Neuro Oncol 2020.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.